Repositori institucional URV
| Autor/s de la URV: | Masana Marín, Luis |
| Autor segons l'article: | Masana, L; de Isla, LP; Moya, GD |
| Adreça de correu electrònic de l'autor: | luis.masana@urv.cat |
| Identificador de l'autor: | 0000-0002-0789-4954 |
| Any de publicació de la revista: | 2024 |
| Tipus de publicació: | Journal Publications |
| Referència de l'ítem segons les normes APA: | Masana, L; de Isla, LP; Moya, GD (2024). Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets. Nutrition Metabolism And Cardiovascular Diseases, 34(1), 90-97. DOI: 10.1016/j.numecd.2023.09.022 |
| Referència a l'article segons font original: | Nutrition Metabolism And Cardiovascular Diseases. 34 (1): 90-97 |
| Resum: | Background and aims: Despite considerable evidence that lipid-lowe ring therapies (LLTs) afford clinical benefit, the control of low-density lipoprotein cholesterol (LDL-C) is suboptimal, and available LLTs are underused, especially in patients at high and very high cardiovascular (CV) risk. This study assesses the real-world LDL-C target attainment rate in patients on LLT before experiencing a first major acute cardiovascular event (MACE). Methods and results: The HEARTBEAT was a retrospective, multicentre observational study. From March to June 2021 a total of 334 patients on LLT who had a first MACE while being on statins were included in the study. Of these patients, 83.2 % had a high (40.7 %) or very high CV risk (29.0 %) prior to MACE. Overall, 87.5 % and 89.7 % of the patients at high and very high CV risk, respectively, failed to reach the LDL-C target. Regarding LLTs, only 11.8 % and 19.6 % of the patients at high and very high risk had received high-intensity LLTs prior to MACE. It was estimated that if these patients had reached their recommended LDL-C targets, the risk of MACE may have been reduced by a median of 24.5 % and 23.2 % in patients at high and very high risk respectively. Conclusions: Patients who suffer a first MACE while on statin therapy often were at high/very high CV risk. Despite their risk, LDL-levels and being on statins they are undertreated, and too far from lipid targets. A proper use of high-intensity LLTs led to an increase attainment of LDL targets and lower CV events. (c) 2023 The Author(s). Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| DOI de l'article: | 10.1016/j.numecd.2023.09.022 |
| Enllaç font original: | https://www.nmcd-journal.com/article/S0939-4753(23)00383-6/fulltext |
| Versió de l'article dipositat: | info:eu-repo/semantics/publishedVersion |
| Accès a la llicència d'ús: | https://creativecommons.org/licenses/by/3.0/es/ |
| Departament: | Medicina i Cirurgia |
| URL Document de llicència: | https://repositori.urv.cat/ca/proteccio-de-dades/ |
| Àrees temàtiques: | Serviço social Saúde coletiva Nutrition and dietetics Nutrition & dietetics Nutrição Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Farmacia Enfermagem Endocrinology, diabetes and metabolism Endocrinology & metabolism Educação física Ciências biológicas ii Ciências biológicas i Ciências ambientais Cardiology and cardiovascular medicine Cardiac & cardiovascular systems |
| Paraules clau: | Spain Safety Risk Primary prevention Population Participants Metaanalysis Lowering therapy Low-density lipoprotein cholesterol Lipid-lowering therapy Ldl-cholesterol Efficacy Coronary-heart-disease Cardiovascular risk |
| Entitat: | Universitat Rovira i Virgili |
| Data d'alta del registre: | 2024-08-03 |
| Cerca el teu registre a: |   |
| Fitxer | Descripció | Format | |
|---|---|---|---|
| DocumentPrincipal | DocumentPrincipal | application/pdf |
© 2011 Universitat Rovira i Virgili